From: Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
Grade
Highest Toxicity Grade for Each Patient (n = 10)
N (%)
1
1 (10%)
2
7 (70%)
3
0
4
5